Skip to main content Skip to navigation

News

New Publication for Warwick Evidence

Armoiry, X., Spath, H.-M., Clarke, A., Connock, M., Sutcliffe, P. & Dussart, C. (2019) Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma. Journal of Market Access & Health Policy, 7 (1): 1648971.

For the full paper see here.


New Publication for Warwick Evidence

Connock, M., Armoiry, X., Tsertsvadze, A., Melendez-Torres, G. J., Royle, P., Andronis, L. & Clarke, A. J. B. C. (2019) Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. 19 (1): 392.

For the full paper see here.

Mon 03 Jun 2019, 15:24

New publication for Warwick Evidence

Taylor-Phillips, S. & Stinton, C. (2019) Fatigue in radiology: a fertile area for future research. Br J Radiol, 20190043.

For the full paper see here

Mon 03 Jun 2019, 15:22

Where next for dry AMD and Stargardt research?

A team from Warwick Medical School reviewed hundreds of articles about possible treatments to identify emerging treatments for the dry form of age-related macular degeneration (AMD), and for Stargardt disease. See here for the full artcile.

Mon 14 Jan 2019, 09:58 | Tags: Warwick Medical School

Older news